Proactive Investors - Run By Investors For Investors

CB2 Insights closes acquisition of cannabis evaluation clinics in Arizona and Colorado

The acquisition of MedEval Clinic provides CB2 with a network of clinics that offer cannabis evaluation and educational services
doctor holding cannabis
The Toronto-based company currently evaluates 65,000 patients annually through its clinic network

CB2 Insights Inc (CSE:CBII) announced Wednesday that it had finalized the acquisition of MedEval Clinic LLC as the data analytics company continues to bolster its presence in southwestern United States.

MedEval Clinic runs a network of health centres in the states of Colorado and Arizona that offer cannabis evaluation and educational services. The company reported around C$1 million in revenue last year.

READ: CB2 Insights acquires Colorado-based Relaxed Clarity in a cash and stock deal; shares rise

CB2 acquired MedEval in a combination of cash and stock with CB2 shelling out US$150,000 in cash as well as 450,000 of its shares worth a deemed value of US$225,000. Additional milestone incentives are in place, which are valued at up to US$300,000.

The new acquisition is in line with CB2’s clinical consolidation strategy, according to CEO Prad Sekar.

“With the completion of this additional 2019 acquisition, CB2 continues to solidify our position as the leading group of multi-state medical cannabis evaluation and education centers in the US,” said CB2’s Sekar.

“These acquisitions not only bring meaningful lift to our top line revenue, they are key to growing our data pool as more and more stakeholders are looking for clinically-validated, evidence-based data to assess the true efficacy of cannabis treatment globally.”

CB2 concentrates on gleaning real-world evidence obtained from data outside randomized trials and generated during routine clinical practice. The company has created what it says are game-changing tools that engage the medical community and provide the data doctors and other professionals need to recommend with confidence cannabis-based medicines.

The Toronto-based company currently evaluates 65,000 patients annually through its clinic network and handles millions of clinically validated data points to advance understanding of the effectiveness and risks associated with cannabinoid therapy.

Shares of CB2 closed at C$0.31 on Tuesday in Toronto.

Ellen Kelleher also contributed to this report

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full CBII profile View Profile

CB2 Insights Timeline

Related Articles

muffins and cannabis
November 29 2018
Dehydratech is essentially a delivery system that allows drugs and vitamins to get into the bloodstream quicker, while making them taste and smell better at the same time
The R&D programme is intended to address the increasing prevalence of obesity and diabetes using smart siRNA
October 30 2018
The health sciences company noted that the plan was formulated at a recently held two-day intensive workshop which together leading scientific teams from the QIMR Berghofer Medical Research Institute in Brisbane and Murdoch University in Perth
cannabis tablet
February 28 2019
The company fills a niche in the medicinal cannabis market, as it continues to push forward its suite of precision oral dose products
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use